BridgeMD
A Phase 2b Study to Evaluate Eltrekibart in Adults with Moderate to Severe Hidradenitis Suppurativa
EU CTIS ID: 2023-505608-43-00
What this study is testing
To test if eltrekibart is superior to placebo in inducing Hidradenitis Suppurativa Clinical Response (HiSCR50) in adult participants with moderate-to-severe HS
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- 1. Have a diagnosis of HS for at least 12 months. 2. Have HS lesions in at least 2 distinct anatomical regions. At least 1 of the lesions must be Hurley Stage II or III. 3. Have an (abscess plus inflammatory nodule) count of at least 5. 4. Agree to use topical antiseptics daily. 5. Had an inadequate response or intolerance to a 28-day course of oral antibiotics.
You likely can't join if
- 1. Have more than 20 draining fistulae. 2. Have had surgical treatment for HS in the last 4 weeks before randomization. 3. Have an active skin disease or condition, that could interfere with the assessment of HS. 4. Have a current or recent acute, active infection. 5. Are immunocompromised. 6. Have a history of chronic alcohol abuse, IV drug abuse, or other illicit drug abuse within 1 year before screening.
The study team makes the final eligibility decision.
Where it's taking place
- Australia
- United States
- Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Australia; United States; Canada. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.